Brokerage firm Jefferies Maintains its rating on Eli Lilly and Co(NYSE:LLY). In a research note issued to the investors, the brokerage major Raises the price-target to $105.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Jul 14, 2016.
In a different note, On May 2, 2016, Leerink Swann said it Maintains its rating on Eli Lilly and Co. In the research note, the firm Raises the price-target to $96.00 per share. The shares have been rated ‘Outperform’ by the firm.
Eli Lilly and Co (LLY) shares turned negative on Mondays trading session with the shares closing down -0.27 points or -0.34% at a volume of 30,87,620. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $80.59. The peak price level was also seen at $80.59 while the days lowest was $79.855. Finally the shares closed at $79.95. The 52-week high of the shares is $92.85 while the 52-week low is $67.88. According to the latest information available, the market cap of the company is $88,252 M.
Eli Lilly and Co has also declared a cash dividend of $0.5100 on Jun 20, 2016. The shares will quote ex-dividend on Aug 11, 2016 and the record date has been fixed on Aug 15, 2016. The dividend payable date has been fixed on Sep 9, 2016.
Eli Lilly and Co(LLY) last announced its earnings results on Apr 26, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.87B. Analysts had an estimated revenue of $4.82B. Earnings per share were $0.83. Analysts had estimated an EPS of $0.85.
Several Insider Transactions has been reported to the SEC. On Jul 13, 2016, Endowment Inc Lilly (10% owner) sold 210,000 shares at $79.54 per share price.Also, On Jun 13, 2016, Melissa S Barnes (Chief Eth/Cmpl Ofcr & SVP, ERM) sold 992 shares at $73.77 per share price.On May 16, 2016, Jackson P Tai (director) purchased 1,080 shares at $75.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.